8M.Needham,F.L.Mastaglia/NeuromuscularDisorders24(2014)4–15
passbytheliver.Atorvastatin,simvastatinandlovastatinaremetabolizedbythecytochromep450(CYP3A4)enzyme,while uvastatinusescytochromep450(CYP2C9).Simvastatinalsohasa nitytoCYP2D6aswellasCYP2C9[104].RosuvastatinandpravastatinarenotmetabolizedbytheCYPenzymesandareeliminatedlargelyasunchangeddrugs[34].ItiswellknownthatconcurrentuseofCYP3A4inhibitorscanraisetheconcentrationofthedrugintheserum,andincreasetheriskoftoxicityincludingrhabdomyolysis.Approximatelyhalfofallprescriptiondrugsaremetabolizedbythispathway[105].Manycasesofstatin-inducedrhabdomyolysisoccurredinassociationwithdrugsinteractingwiththissystem,particularlygem brozil[17].Geneticpolymorphismscancauseincreasedenzymeactivityresultinginanelevateddruglevelandthereforepotentialtoxicity,oradecreasedorabsentenzymeactivityresultinginalackoftherapeutice cacy[106].WhilstCYP3A4isthemostimportant,itdoesnothavemanypolymorphisms[105],andthusfardoesnotseemtobeassociatedwithstatin-inducedmusclee ects[107,108].CYP2D6ontheotherhandhashadmorethan50variantsdescribed,allowingsubgroupsofpoormetabolizers,extensivemetabolisersandultrarapidmetaboliserstobede ned[109].Mulderandcolleagues[110]analysedtheCYP2D6genotypesin88simvastatin-treatedpatients,andfoundthehighestincidenceofintolerabilityinthehomozygouspatientsforthe‘defective’CPY2D6allelesleadingtodecreasedenzymeactivity,butastatisticallysigni cantlargerdecreaseinserumcholesterol.Zuccaroontheotherhandfoundpoormetabolisersdidnothaveanincreasedrate
Table2
Geneticpolymorphismsreportedtobeassociatedwithstatin-myopathy.
Study
Statin
Outcomesmeasured
Genesinvestigated*
Singlenucleotidepolymorphism(SNP)oralleleassociatedwiththemeasuredoutcome
c.521CCgenotypeofSLCO1B1a ectspharmacokineticsofpravastatinSLCO1B1*5allele(mostsigni cantforsimvastatin)
c.521CCgenotypea ects
pharmacokineticsofsimvastatinacidrs4149056SNP(intheCallele)
Statin
transporterproteins
Niemietal.[93,96]Pravastatin(n=32)FluvastatinVoora[94](n=509)Simvastatin
AtorvastatinPravastatin
Pasanen[95]Simvastatin(n=32)
SEARCH[97]Simvastatin(n=175initial)
Pharmacokinetics,(plasmaconcentration)
Drugdiscontinuation,myalgia,HyperCKaemia,Pharmacokineticsofsimvastatinacid
Myopathyandcholesterolloweringe ects
SLCO1B1
CYP2D6,CYP2C8,CYP2C9,CYP3A4/SLCO1B1SLCO1B1
Genomewidestudywith>300,000markers,(IlluminaHumanHap300-Duopanel),CYP3A4/SLCO1B1SLCO1B1gene
Donnelly[98](n=4196)
Multiple(majoritysimvastatin)
Fiegenbaumetal.[102](n=116)
Simvastatin
Statinintolerance
(biochemical,discontinuationofdrug,switchingorreducingdoseofdrug),andcholesterolloweringe ect
ReductioninserumCYP3A4,CYP3A5,cholesterolandLDLsABCB1
rs4149056(Val174Ala)associatedwith
higherintolerance,rs2306283
(Asp130Asn)associatedwithlowerintolerance
1236Talleleand2677G>A/T
polymorphisminABCB1genehadmoresigni cantreductionsinserumcholesterolandLDL
Reducedfrequencyof1236T,2677non-Gand3435Thaplotypesinpatientswithmyalgia
CYP2D6*4(G1934mutation),CYP2D6*3(A2637deletion)andCYP2D6*5(CYP2D6genedeletion)(associatedwith‘poormetaboliser’phenotype).Homozygosityassociatedwithhighestincidenceintolerabilityandstrongerdecreaseinserumcholesterol*
4alleleassociatedwithmuscleevents
Presenceofmyalgia’s
Statin
metabolismgenes
Mulderetal.[110](n=88)
Simvastatin
DiscontinuationoftherapyCYP2D6duetoadverseevents
(gastrointestinal>myalgia’s),ande cacyofcholesterollowering(serumcholesterollevels)
Frudakisetal.[108]Atorvastatin,Frequencyofmuscleevents(n=263samples)Simvastatin(myalgia,CKelevation,
rhabdomyolysis)
Wilkeetal.[107]AtorvastatinElevatedCKandpresence(n=137)myalgia
CYP2D6(388SNP’s
investigated)CYP3A
CYP3A5*3allele(noincreasein
incidenceofmyopathy,buthigherCKrisesinhomozygotesexperiencingmyalgia)
热门文档